Abstract
The Anglo-Scandinavian Cardiac Outcomes Lipid Lowering Arm (ASCOT-LLA) has recently been terminated early due to significant reductions in major cardiovascular events amongst patients taking atorvastatin. This article summarises the study and considers its implications for clinical practice.
Get full access to this article
View all access options for this article.